Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To demonstrate the bioequivalence of Azithromycin 600 mg Tablets Under Fed Conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Azithromycin Monohydrate 600mg Tablets |
|
| 2 | Active Comparator | Zithromax (azithromycin dihydrate)600mg Tablets |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Azithromycin Monohydrate 600 mg Tablets | Drug |
| ||
| Zithromax (azithromycin dihydrate) 600 mg Tablets |
| Measure | Description | Time Frame |
|---|---|---|
| Bioequivalence according to US FDA guidelines | 32 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alan S. Marion, M.D. | MDS Pharma Services | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D007239 | Infections |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017963 | Azithromycin |
| ID | Term |
|---|---|
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D009930 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| Organic Chemicals |